Metformin is the first-line pharmaceutical treatment drug for T2DM because it specifically reduces hepatic gluconeogenesis without increasing insulin secretion, inducing weight gain, or posing a risk of hypoglycemia [9]. This evidence concerns the gene INS and type 2 diabetes mellitus.